# EPCORE DLBCL-3 (NCT05660967)

> Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05660967
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Genmab
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: Epcoritamab; Lenalidomide
- Enrollment: 111
- Primary outcome: Complete Response (CR) rate

## HCP commentary on EPCORE DLBCL-3 so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 3
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=epcore-dlbcl-3-nct05660967

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05660967", "email": "<work email>"}; the inbox owner confirms by the emailed link.